Abseamed

Quick links to important sections

Abseamed

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Abseamed

Quick Facts

Property Description
Active ingredient Epoetin alfa (Recombinant human erythropoietin)
Form Solution for injection (Pre-filled syringe/Vial)
Pharmacological class Erythropoiesis-Stimulating Agent (ESA)
Common use Prevention and correction of symptomatic anemia
Origin Biologic / Biosimilar medicine

What Type of Medicine is Abseamed (Epoetin Alfa)?

Abseamed is a biological medicine classified as an Erythropoiesis-Stimulating Agent (ESA), whose active ingredient is Epoetin alfa. This substance is a high-purity recombinant human erythropoietin (r-HuEPO), a complex glycoprotein molecule.

Abseamed is authorized as a specific biosimilar medicine, which means it is considered highly similar to an original reference biologic and has been shown to have equivalent efficacy. The Epoetin alfa is manufactured using advanced recombinant DNA technology within Chinese Hamster Ovary (CHO) cells, resulting in a protein that precisely mimics the natural erythropoietin (EPO) hormone produced in the kidneys.


Composition and General Therapeutic Purpose

The primary purpose of Abseamed is to address symptomatic anemia by actively promoting the increase of red blood cells and hemoglobin. The medication is a single-ingredient product, containing the active Epoetin alfa dissolved in a sterile aqueous solution base. As a Growth Factor, it provides a direct signal to the bone marrow to accelerate erythropoiesis (red blood cell formation).

This mechanism supports a sustained, internal generation of blood cells. The core benefit is the restoration of the blood's oxygen-carrying capacity, which is essential for relieving the fatigue and weakness often associated with low blood counts, such as those related to chronic illnesses.


What is the Physical Form of Abseamed?

Abseamed is supplied as a sterile solution for injection in an injectable form, typically provided in a pre-filled syringe or vial. This presentation is strictly necessary because the Epoetin alfa molecule, like other protein-based biologics, cannot survive the digestive process if taken orally. The product is administered via the subcutaneous route (under the skin) or the intravenous route (into a vein). This injectable format offers necessary flexibility for managing the care of target patient groups.

Regulatory References

  1. Epoetin Alfa production details

What side effects are possible with Abseamed?

Possible Side Effects and Safety Information

Abseamed (epoetin alfa) has a safety profile documented in official regulatory sources, with adverse reactions categorized by frequency and system-organ class.

Frequency and System Classification

Classification System-Organ Class Examples (Regulatory Terminology)
Very Common Vascular Disorders Hypertension (high blood pressure)
Very Common Nervous System Headache
Common Vascular Disorders Thromboembolic events (e.g., blood clots)
Common General Disorders Pyrexia (fever), Flu-like symptoms (initial)
Uncommon Immune System Hypersensitivity reactions
Rare Blood and Lymphatic System Pure Red Cell Aplasia (PRCA)

Serious Adverse Reactions and Safety Limitations

Serious Adverse Reactions officially documented include Thromboembolic Events (such as stroke, myocardial infarction, or deep vein thrombosis) and the rare, but severe, immunologically-mediated condition Pure Red Cell Aplasia (PRCA).

Population-Specific Safety: Patients with Chronic Kidney Disease (CKD) are noted to have greater risks for serious cardiovascular events and stroke when hemoglobin targets are exceeded (e.g., above 11 g/dL) as per FDA and EMA prescribing information. Use is also associated with an increased risk of seizures in CKD patients, particularly during the first 90 days of treatment.

Safety-Related Restrictions: The medicine is contraindicated (should not be used) in patients with uncontrolled hypertension or a history of PRCA following previous epoetin treatment. The official label requires close monitoring of blood pressure prior to and throughout therapy. Iron status must also be assessed and maintained for appropriate response.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Abseamed (epoetin alfa) results from an exaggerated pharmacological effect, which primarily manifests as polycythaemia—an abnormally high concentration of haemoglobin and red blood cells in the blood. The maximum dose that can be tolerated has not been determined in studies.

Clinical Manifestations and Risk Factors

The principal risk in overdosage is sustaining a haemoglobin level greater than 12 g/dL (7.5 mmol/L), which should be strictly avoided as part of dose management to prevent serious complications. An additional, severe manifestation associated with overexposure is toxic leukoencephalopathy, which affects the central nervous system.

Required Emergency Actions

If excessive polycythaemia occurs, the official guidance requires temporary withholding of Abseamed treatment. If medically indicated for severe polycythaemia, a procedure known as phlebotomy (therapeutic blood withdrawal) may be performed to reduce the red blood cell count.

Urgent medical attention is required for any signs suggesting severe polycythaemia, its complications (such as excessive blood thickening), or symptoms related to central nervous system effects like toxic leukoencephalopathy, to ensure immediate clinical management.

Therapeutic Uses of Abseamed

What Abseamed Treats: Main Uses and Benefits

Abseamed is commonly used to provide supportive therapeutic benefit across clinical domains where patients experience symptoms related to systemic imbalance, specifically symptomatic anaemia. This medication is relevant for easing symptoms associated with anaemia (low red blood cell counts) in relevant contexts, including those with chronic kidney disease and certain conditions associated with increased physiological stress.

The medicine is applied in addressing specific symptoms that interfere with daily comfort and create noticeable physiological strain. It is commonly used when short-term symptomatic assistance is needed, as it contributes to improved day-to-day comfort during symptomatic periods.

“Abseamed is used to provide symptomatic relief and supports with maintaining functional stability when symptoms become intense or disruptive.”

This medication is considered relevant in conditions characterized by periods of heightened symptoms where groups of symptoms appear suddenly or fluctuate quickly. It helps to ease the overall symptom load associated with major episodic changes, offering symptomatic relief that may help patients cope more steadily with difficult episodes.


Quick Fact: Relief for Symptoms that Interfere with Daily Functioning


Eligibility and Restrictions for Use

Abseamed (Epoetin alfa) eligibility is strictly defined by regulatory bodies to limit its use to specific patient populations and conditions.

Populations for Whom Use is Allowed

Use is sanctioned for adults and children aged 1 to 18 years with symptomatic anemia due to Chronic Renal Failure (CRF). It is also approved for certain adult cancer patients undergoing myelosuppressive chemotherapy and for specific adults scheduled for major elective surgery (non-cardiac, non-vascular) with moderate anemia. Adults with low- or intermediate-1-risk Myelodysplastic Syndromes (MDS) are also eligible under specific laboratory criteria.


Populations for Whom Use is Contraindicated

The medicine must not be used in patients with uncontrolled hypertension or a known severe allergy to epoetin alfa or its components. It is also absolutely contraindicated in patients with a history of Pure Red Cell Aplasia (PRCA) following prior treatment with any erythropoietin product. Preservative-containing formulations are contraindicated in neonates, infants, and pregnant or lactating women.


Age and Condition-Based Restrictions

Safety has not been established for infants with CRF under mathbf1 month old. Use is restricted in all eligible patients to ensure the hemoglobin level does not exceed mathbf12 g/dL; exceeding this official threshold increases cardiovascular and thromboembolic risks. For pregnant and lactating women, use is highly restricted and permitted only after a risk-benefit assessment, mandating the use of preservative-free formulations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Abseamed (Epoetin alfa), a biologic medicine, has officially documented interaction patterns that focus primarily on its pharmacodynamic effects and formulation constraints rather than classic metabolic interactions.

Pharmacodynamic and Secondary Pharmacokinetic Interactions

Co-administration with Androgens may lead to a pharmacodynamic increase in the red blood cell response. This additive effect is formally noted in regulatory documents.

Epoetin alfa can also impact the blood levels of certain co-administered drugs, such as the immunosuppressant Cyclosporine. As the red blood cell mass increases during treatment, it may indirectly cause a reduction in Cyclosporine plasma concentration, necessitating regulatory guidance for monitoring its levels.

Formulation-Based Restriction

Specific formulations, such as multiple-dose vials containing Benzyl Alcohol, are subject to a contraindication by regulatory agencies in specific populations. Use of the benzyl alcohol preservative is prohibited in neonates, infants, pregnant women, and nursing women.

Nutritional Co-Factor Dependence

The efficacy of Abseamed is critically dependent on the presence of sufficient Iron, Folate, and Vitamin B12. Official labeling documents state that deficiencies in these co-factors are associated with a suboptimal or absent therapeutic response and must be corrected to ensure the drug’s desired action.

Mechanism of Action

How Abseamed Works

Abseamed (Epoetin alfa) functions as a precise molecular substitute for the natural human hormone, erythropoietin, engaging a specific biological cascade to modulate red blood cell production.

Activation of the Erythropoietin Receptor (EPO-R) Agonism

The drug's mechanism initiates through receptor agonism, binding to and activating the Erythropoietin Receptor (EPO-R) on committed erythroid progenitor cells in the bone marrow. This signal is necessary to promote the proliferation and differentiation of these precursor cells into the erythroid lineage.

Intracellular JAK2/STAT5 Signaling Cascade

Binding to the EPO-R initiates a complex intracellular signaling cascade, notably activating the JAK2/STAT5 pathway. This signal suppresses apoptosis and drives the proliferation and accelerated differentiation of the progenitor cells, accelerating the process of erythropoiesis.

Systemic Hematological Consequence

The sustained increase in the output of mature red blood cells (erythrocytes) from the bone marrow leads to an elevation in the body's circulating hemoglobin concentration. This process increases the concentration of circulating hemoglobin, which elevates the blood’s oxygen-carrying capacity.

Dosage and Administration Information

Administration of Abseamed

Abseamed is typically administered by a healthcare professional, such as a doctor or nurse. In certain cases, individuals may be trained to administer the medication themselves through an injection under the skin (subcutaneously). The medication can also be administered directly into a vein (intravenously).

Preparation and Handling

Before use, the solution should be inspected visually. It should only be used if the liquid is clear, colorless, and free of visible particles. The pre-filled syringe should be allowed to reach room temperature before the injection is performed. This usually takes between 15 and 30 minutes.

To maintain the stability of the medication:

  • Do not shake the syringe, as vigorous shaking may damage the protein.
  • Only one dose should be taken from each syringe.
  • Any remaining product left in the syringe after the dose must be discarded.

Self-Administration

If a healthcare provider determines that self-administration is appropriate, specific training on the correct injection technique is required. This includes instructions on how to prepare the injection site, how to use the pre-filled syringe, and how to safely dispose of used needles and syringes.

Rotation of Injection Sites

When Abseamed is injected under the skin, it is important to rotate the injection site for each dose. Common areas for subcutaneous injection include the upper arms, the abdomen (avoiding the area around the navel), or the front of the thighs. Avoiding the same spot for consecutive injections helps prevent skin irritation or the development of fatty tissue deposits at the site.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Abseamed

Evidence for Use in Symptomatic Anemia due to Chronic Kidney Disease (CKD)

Research has primarily focused on the use of Abseamed for symptomatic anemia in patients with Chronic Kidney Disease (CKD), which is one of the contexts in which it was studied for. The core evidence consists of Randomized Controlled Trials (RCTs), including comparative studies research examined to assess similarity (biosimilarity) to the original reference medicine. These studies monitored patient populations that include adults and children, encompassing those on dialysis as well as patients with renal insufficiency who were not yet undergoing dialysis.

The main focus of these trials was studying outcomes related to systemic or functional imbalance, specifically Hemoglobin (Hb) concentrations and the assessment of whether a patient needed a blood transfusion. The findings describe patterns observed in the studies, where Hemoglobin measurements fell within pre-defined ranges that were monitored to support the assessment of comparability of the biosimilar.

Evidence for Use in Anemia During Chemotherapy

Abseamed was evaluated in studies for patients with anemia related to chemotherapy for specific types of cancer, such as solid tumors, malignant lymphoma, or multiple myeloma. These clinical trials often used a placebo-controlled design. The research primarily examined the rate of allogeneic Red Blood Cell (RBC) transfusions required by patients during their treatment cycles, and monitored the evolution of Hemoglobin levels and Quality of Life (QoL). Research has explored raising Hemoglobin levels above 12 g/dL, but findings from those trials show patterns related to an increased risk of thromboembolic events.

Research Gaps and Areas of Uncertainty

Certainty remains low regarding the ideal maximum Hemoglobin level that can be safely targeted in CKD patients due to the safety patterns observed in some studies. Comparative evidence is lacking for many long-term outcomes, as the trials mainly focused on short-term efficacy measures. Research is ongoing through post-marketing surveillance, and the evidence highlights what is known, and what is still uncertain, especially regarding long-term cardiovascular outcomes and overall survival in certain cancer settings.

Key Studies & References

  1. A Phase III, randomized, open-label, comparative study to assess the efficacy and safety of epoetin alfa biosimilar (HX575) and epoetin alfa (Eprex) in patients with chronic renal failure
  2. NICE Guideline NG8: Anaemia management in people with chronic kidney disease

Frequently Asked Questions (FAQ)

Common questions about Abseamed (FAQ)

Q: Is Abseamed a type of chemotherapy?

A: According to official product information, Abseamed is classified as an Erythropoiesis-Stimulating Agent (ESA), a type of biologic medicine. This classification means its purpose is to stimulate the production of red blood cells. It is not considered a chemotherapy drug.

Q: How is Abseamed different from other similar treatments I've heard about?

A: Regulatory documents describe Abseamed as a biosimilar medicine. This means it has been shown to be highly similar to the original reference medicine, Epoetin alfa, in terms of quality, safety, and how it works. It functions in the same way as the natural hormone erythropoietin to stimulate red blood cell formation.

Q: What is the difference between a biosimilar and the original Epoetin alfa drug?

A: A biosimilar is a biological medicine that has been authorized after demonstrating it is highly similar to an original, already-authorized reference biologic. It has been shown through comparative studies to have equivalent efficacy and to meet the same quality and safety standards as the original product.

Q: Are the safety standards for biosimilars like Abseamed the same as the original drug?

A: Yes, a medicine can only be authorized as a biosimilar after rigorous comparative studies have confirmed it meets the exact same strict quality and safety standards as the original reference product. This process is mandated by regulatory bodies to ensure that it has equivalent safety and efficacy.

Q: How quickly does Abseamed start to have an effect?

A: The goal of treatment is to achieve a controlled, gradual increase in the target hemoglobin level. Because of this, healthcare providers typically do not adjust the dose more frequently than once every four weeks. This indicates that the drug's full therapeutic effect takes time to be measured and achieved.

Q: Does Abseamed make you feel immediately better?

A: Official guidelines state that this medicine is not a substitute for a red blood cell transfusion when immediate correction of anemia is necessary. Clinical goals focus on the gradual restoration of oxygen-carrying capacity as blood counts improve, rather than immediate subjective improvement.

Q: How long does the effect of one injection of Abseamed last?

A: The medicine is typically administered on a set schedule, often three times per week or sometimes once weekly, to ensure a sustained therapeutic level. The required frequency of administration is determined by a healthcare provider based on the treated condition and clinical response.

Q: Can Abseamed be taken at the same time as my blood pressure medication?

A: Official guidelines state that Abseamed is contraindicated in patients with uncontrolled hypertension (very high blood pressure). Since controlled blood pressure is necessary during treatment, healthcare providers often ensure that patients continue their blood pressure medication as prescribed. Official guidance emphasizes the need for close blood pressure monitoring throughout therapy.

Q: Is Abseamed safe for people who are older than 65?

A: The official product information uses the same general dosing and safety instructions for all adults, including those over 65. This indicates that specific dose adjustments based solely on being over the age of 65 are not typically mandated by regulatory guidelines.

Q: Can people with a history of heart problems use Abseamed?

A: Official documents note that patients with a history of certain heart problems, including prior heart attack, stroke, or congestive heart failure, may have an increased chance of side effects. For this reason, use requires careful assessment and close monitoring by a healthcare provider.

Q: What happens if I miss an appointment for my Abseamed injection?

A: Regulatory dosing instructions are based on maintaining the hemoglobin level within a target range. If a dose is missed, a healthcare provider uses established guidelines for dose management, which includes adjusting or potentially withholding the dose based on the patient's current hemoglobin level.

Q: Does Abseamed cause weight gain or loss?

A: Official documents list changes in weight as potential adverse reactions. Weight decrease has been observed in some clinical studies, such as those involving cancer patients. Conversely, weight gain along with swelling of the extremities is noted as a common side effect in other patient groups, such as those with chronic kidney disease.

Q: Can Abseamed affect sleep patterns?

A: According to official product labeling, insomnia (trouble sleeping) is listed as a potential adverse reaction. This has been noted particularly in clinical studies involving patients who were receiving the medicine for anemia related to chemotherapy.

Q: Is it normal to feel a stinging sensation during the injection?

A: Official patient guidance acknowledges that pain and redness at the injection site are common side effects that can occur, especially at the start of treatment. Official patient guidance suggests alternating injection sites may help manage this localized discomfort.

Q: What is the maximum duration a person can be treated with Abseamed?

A: The duration of treatment is individualized and based on the specific condition being treated and the patient's response. Treatment may be discontinued if there is no satisfactory response after a period of dose escalation, or upon completion of a chemotherapy course for cancer patients.

Q: What should I do if I notice swelling after the injection?

A: Swelling of the face, lips, tongue, or throat, especially when combined with a rash or difficulty breathing, can be a sign of a severe allergic reaction and should be reported immediately to a healthcare professional. Separately, general swelling of the lower legs, feet, or ankles is noted as a common side effect in some patient groups.

Q: What does 'contraindication' mean in the context of Abseamed?

A: According to medical reference sources, a contraindication is an absolute condition or specific situation in which a medicine must not be used. This is because using the drug in that context carries an unacceptably high risk of harm or adverse effects.

Q: Will I need to change my lifestyle while on Abseamed?

A: The official label requires close and frequent monitoring of blood pressure and adherence to instructions regarding iron supplementation. This need for routine health monitoring and compliance with other instructions constitutes a required change in a patient's normal routine.

Q: Are there any long-term side effects associated with Abseamed use?

A: Official regulatory warnings highlight that the use of this medicine is associated with risks, particularly when the hemoglobin target is set above 11 g/dL. Exceeding this threshold is associated with increased long-term risks for death, serious adverse cardiovascular reactions, and stroke in certain patient groups.

Q: What are the signs that Abseamed is not working for me?

A: A lack of expected effect is defined by laboratory measures. This includes if the hemoglobin level has not increased by more than 1 gram per deciliter after four weeks of therapy, or if the patient continues to require frequent red blood cell transfusions.

Q: What kind of specialist typically prescribes or manages treatment with Abseamed?

A: Official product information requires that treatment be started and monitored under the supervision of a doctor who has experience in the management of patients with the condition being treated. This often includes specialists like nephrologists (for kidney disease) or oncologists (for cancer).

Q: Are there different strengths or versions of Abseamed?

A: Yes, Abseamed is available in pre-filled syringes of various strengths for injection. This range of available strengths allows for the individualized dose calculation required for each patient's treatment regimen.

Q: Do you get less tired after starting Abseamed?

A: Studies and official information indicate that treatment with Epoetin alfa is associated with a reduction in fatigue and an improvement in overall Quality of Life in anemic patients, such as those undergoing chemotherapy. This is a known goal of restoring the blood's oxygen-carrying capacity.

Q: Are there specific symptoms that require immediate medical attention while on Abseamed?

A: These serious symptoms, such as signs of a blood clot (e.g., sudden trouble speaking, pain or swelling in the leg) or signs of a serious heart problem (e.g., chest pain, shortness of breath), should be reported to a healthcare provider immediately.

Q: Does taking Abseamed require routine blood tests?

A: Yes, official regulatory labels confirm that routine blood tests are necessary to check progress regularly, monitor for unwanted effects, and ensure that key levels, such as hemoglobin and iron status, are maintained correctly.

Q: What is the meaning of the warning about Pure Red Cell Aplasia (PRCA) for Abseamed?

A: Pure Red Cell Aplasia (PRCA) is a rare but very serious condition that has been associated with epoetin treatment. It occurs when the body produces antibodies that stop the bone marrow from making red blood cells, which can lead to a sudden, severe form of anemia.

How should Abseamed be stored and disposed of?

Storage and Disposal of Abseamed

Abseamed (Epoetin alfa) requires strict adherence to labeled conditions to maintain the stability of this biological medicine.


Mandatory Storage Conditions

Condition Requirement
Temperature Store in a refrigerator between 2 C and 8 C.
Protection Keep in the original carton to protect from light.
Freezing Do not freeze; discard the product if it has been frozen.
Child Safety Keep out of the sight and reach of children.

Shelf-Life and Disposal Rules

Temporary Excursion: The unopened product may be stored once for a single period of up to 30 days at a temperature not exceeding 25 C. If not used within this 30-day period, it must be discarded.

Disposal: Unused or expired medicine must be disposed of according to local requirements and must not be discarded via wastewater or household waste. Used needles and syringes (sharps) must be placed in an approved puncture-resistant sharps disposal container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Abseamed found in:

A-Z Index: